Handok's locally advanced or metastatic cholangiocarcinoma treatment Pemazyre received domestic product approval on the 25th. The Ministry of Food and Drug Safety (Minister Oh Yoo-kyung) announced that it had approved three doses (4.5mg, 9mg, 13.5mg) of Pemazyre, an orphan drug. Pemazyre is an oral FGFR inhibitor that inhibits the proliferation of cancer cells caused by the fusion or rearrangement of fibroblast growth factor receptor 2 (FGFR2), which is involved in cell growth and differentiation. It is expected to provide a new treatment opportunity for adult patients with locally advanced or metastatic cholangiocarcinoma with FGFR2 fusion or rearrangement who have received one or more systemic treatments. Pemazyre i